Biocon shares zoom ~2% after drug launch in Japan

21 May 2025 , 11:41 AM

Biocon Limited witnessed a gain of over 2% in its stock price in Wednesday morning trade after its subsidiary announced that its commercial partner in Japan launched the Ustekinumab BS Subcutaneous. 

As per the company, this drug shall be used for treating psoriasis vulgaris and psoriatic arthritis.

At around 11.27 AM, Biocon was trading 2.32% higher at ₹340.20, against the previous close of ₹332.60 on NSE. The counter touched an intraday high and low of ₹340.80 and ₹333.35, respectively.

The Ustekinumab BS Subcutaneous injection is a biosimilar to the reference product Stelara (ustekinumab). As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc. marketed and commercialised the drug in Japan.

In April 2024, the company inked a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland and Johnson & Johnson for commercialisation of Ustekinumab in Japan after getting approval from regulatory authorities.

Back in December 2024, the Pharmaceuticals and Medical Devices Agency of Japan approved Biocon Biologics’ biosimilar.

The business has already introduced the drug in the European and US markets earlier in February.

Biocon’s results for the quarter ended March 2025 were better than street estimates, driven primarily by its generic business.

For feedback and suggestions, write to us at [e-mail]